These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22986949)

  • 1. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
    Cuzin L; Trabelsi S; Delobel P; Barbuat C; Reynes J; Allavena C; Peytavin G; Ghosn J; Lascoux-Combe C; Psomas C; Corbeau P; Flandre P;
    J Acquir Immune Defic Syndr; 2012 Dec; 61(5):557-64. PubMed ID: 22986949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
    van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
    PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
    Ripa M; Pogliaghi M; Chiappetta S; Nozza S; Soria A; Coppalini G; Rovelli C; Tambussi G
    J Clin Virol; 2016 Dec; 85():86-89. PubMed ID: 27865174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
    Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
    Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.
    van Lelyveld SF; Symons J; van Ham P; Connell BJ; Nijhuis M; Wensing AM; Hoepelman AI
    Int J Antimicrob Agents; 2016 Jan; 47(1):84-90. PubMed ID: 26585497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.
    Beliakova-Bethell N; Jain S; Woelk CH; Witt MD; Sun X; Lada SM; Spina CA; Goicoechea M; Rought SE; Haubrich R; Dubé MP
    Antiviral Res; 2014 Jul; 107():42-9. PubMed ID: 24769244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
    Tiraboschi JM; Niubo J; Curto J; Podzamczer D
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):606-9. PubMed ID: 20706127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
    Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
    Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues.
    Manfredi R; Calza L; Marinacci G; Cascavilla A; Colangeli V; Salvadori C; Martelli G; Appolloni L; Puggioli C; Viale P
    Infez Med; 2015 Mar; 23(1):36-43. PubMed ID: 25819049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
    Mills A; Mildvan D; Podzamczer D; Fätkenheuer G; Leal M; Than S; Valluri SR; Craig C; McFadyen L; Vourvahis M; Heera J; Valdez H; Rinehart AR; Portsmouth S
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):164-70. PubMed ID: 23187936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
    Wilkin TJ; Lalama CM; McKinnon J; Gandhi RT; Lin N; Landay A; Ribaudo H; Fox L; Currier JS; Mellors JW; Gulick R; Tenorio AR
    J Infect Dis; 2012 Aug; 206(4):534-42. PubMed ID: 22740718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
    Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
    Minami R; Takahama S; Kaku Y; Yamamoto M
    J Infect Chemother; 2017 Jan; 23(1):29-34. PubMed ID: 27729193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of maraviroc on HIV disease progression-related biomarkers.
    Romero-Sánchez MC; Machmach K; Gonzalez-Serna A; Genebat M; Pulido I; García-García M; Alvarez-Ríos AI; Ferrando-Martinez S; Ruiz-Mateos E; Leal M
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5858-64. PubMed ID: 22948867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.
    Chan ES; Landay AL; Brown TT; Ribaudo HJ; Mirmonsef P; Ofotokun I; Weitzmann MN; Martinson J; Klingman KL; Eron JJ; Fichtenbaum CJ; Plants J; Taiwo BO
    AIDS; 2016 Aug; 30(13):2091-7. PubMed ID: 27281061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
    Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
    Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
    AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
    Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S;
    HIV Med; 2018 Jan; 19(1):65-71. PubMed ID: 28703491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
    Macías J; Recio E; Márquez M; García C; Jiménez P; Merino D; Muñoz L; Pasquau J; Ojeda G; Bancalero P; Chueca N; Pineda JA
    HIV Med; 2014 Aug; 15(7):417-24. PubMed ID: 24580801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.